516526-40-2

Basic information

• Product Name: Ethanone, 1-[4-Methoxy-2-nitro-5-(phenylMethoxy)phenyl]-
• Synonyms: Ethanone, 1-[4-Methoxy-2-nitro-5-(phenylMethoxy)phenyl]-;1-(5-(Benzyloxy)-4-Methoxy-2-nitrophenyl)ethanone
• CAS NO: 516526-40-2
• Molecular Formula: C₁₆H₁₅NO₅
• Molecular Weight: 301.294
• Mol File: 516526-40-2.mol

Chemical Properties

• Boiling Point: 488.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.247±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethanone, 1-[4-Methoxy-2-nitro-5-(phenylMethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[4-Methoxy-2-nitro-5-(phenylMethoxy)phenyl]-(516526-40-2)
• EPA Substance Registry System: Ethanone, 1-[4-Methoxy-2-nitro-5-(phenylMethoxy)phenyl]-(516526-40-2)

Safety Data

• Hazardous Substances Data: 516526-40-2(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 6100-74-9 3-hydroxy-4-methoxyacetophenone 
• 23428-77-5 1‐(3‐(benzyloxy)‐4‐methoxyphenyl)ethanone 

Downstream Products

• 516526-41-3 1‐(2‐amino‐5‐(benzyloxy)‐4‐methoxyphenyl)ethanone 

Relevant articles and documents

Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer

In this investigation, a novel series of quinoline analogues bearing thiazolidinones were designed and synthesized based on our previous study. Among them, the most potent compound 11k, 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)phen

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors

Based on the cabozantinib scaffold, novel c-Met inhibitors were rationalized from the limited knowledge of structure-activity relationships for the quinoline 6-position. Emphasis was given to modifications capable of engaging in additional polar interacti

Substituent effects at the benzyl position and aromatic ring of silane-coupling agents containing 2-nitrobenzyl esters on photosensitivity and hydrophobic surface of a self-assembled monolayer (SAM)

Silane-coupling agents with 2-nitrobenzyl esters containing alkyl substituents at the benzyl position and alkoxy and/or fluoroalkoxy groups of the aromatic ring were synthesized to prepare a self-assembled monolayer (SAM) on quartz glass, silicon wafer and thermally oxidized silicon wafer. The resulting photosensitive SAMs before and after photoirradiation were characterized by contact angle measurement, UV spectroscopy, X-ray photoelectron spectroscopy (XPS), and X-ray reflectivity (XRR). Photosensitivity of the SAM was influenced by substituents at the benzyl position and aromatic ring as well as the irradiation conditions in air or solution and substrates employed. Silane-coupling agents with bulky substituent at the benzyl position and double fluoroalkoxy chains are preferable in terms of the photosensitivity and hydrophobic surface.

FLUORINE-CONTAINING COMPOUND, PATTERN FORMING SUBSTRATE, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMING METHOD, COMPOUND, AND ORGANIC THIN FILM TRANSISTOR

PROBLEM TO BE SOLVED: To provide a compound that has a big difference in contact angle before and after light irradiation and is useful as a coupling agent, and an organic thin film transistor prepared by using the compound. SOLUTION: A fluorine-containin

QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

An objective of the present invention is to provide compounds and pharmaceticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.

QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS

An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents 0 or S; Q represents NR10, CR11R12, carbonyl, O, S(=O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.